Prescient Therapeutics Ltd has released a press release.
September Quarterly Updated and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- Appendix 4E and 2025 Annual Report
- Prescient successfully completes $3 million Placement
- June 2025 Quarterly Update and Appendix 4C
- Prescient announces results of SPP & Launches Placement
- Trading Halt
Later from Prescient Therapeutics
- PTX secures EU Orphan Drug Designation for PTX-100 in CTCL
- PTX secures EU Authorisation to commence PTX-100 Trial
- December 2025 Quarterly Update and Appendix 4C
- Appendix 4D and Half Year Financial Report
- March 2026 Quarterly Update and Appendix 4C
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics